Retrospective Cohort Study
Copyright ©The Author(s) 2017.
World J Hepatol. Jul 18, 2017; 9(20): 884-895
Published online Jul 18, 2017. doi: 10.4254/wjh.v9.i20.884
Table 1 Baseline characteristics for patients who had primary liver transplantation and those who had liver retransplantation
VariablesPLT (n = 1090)LRT (n = 150)P value
Demographic
Age54 (18-82)46 (18-72)< 0.001
Gender (male, %)736 (67.5)80 (53.3)0.001
Etiology
ALD (%)345 (31.7)18 (12.0)< 0.001
Viral (%)303 (27.8)50 (33.3)0.159
Cholestatic and autoimmune (%)227 (20.8)34 (22.7)0.604
Clinical
Na, mmol/L135 (116-151)138 (118-150)< 0.001
Creatinine, mg/dL1.0 (0.4-6.8)1.3 (0.7-8.3)< 0.001
Bilirubin, mg/dL2.7 (0.2-68.4)4.7 (0.4-56.3)< 0.001
INR1.3 (0.8-5.0)1.2 (0.8-13.0)0.078
MELD14 (6-40)20 (6-40)< 0.001
UKELD55 (43-77)56 (44-79)0.041
Ascites (%)669 (62.9)38 (25.5)< 0.001
Encephalopathy (%)350 (33.0)52 (34.9)0.637
Table 2 Factors associated with waiting list mortality in liver retransplantation patients on univariate and multivariate Cox proportional hazard analysis
VariableUnivariate
Multivariate
HR95%CIP valueHR95%CIP value
Age > 60 yr2.9590.550-3.8960.0483.1021.015-9.4840.047
DM1.5870.499-5.0420.434
Renal impairment4.7711.496-15.2170.0083.8021.147-12.6030.029
CCI continuous3.1211.589-6.1300.0012.6881.222-5.9120.014
CCI dichotomous6.5281.472-28.9620.0145.4751.177-25.4640.030
Hb, g/dL0.7550.545-1.0470.092
Platelet count, × 109/mL0.9940.986-1.0010.090
Bilirubin, mg/dL1.0120.979-1.0450.481
Creatinine, mg/dL3.2001.888-5.421< 0.0012.6911.261-5.7400.010
INR1.4891.055-2.1020.0241.4060.967-2.0440.075
Encephalopathy2.0490.620-6.7700.239
Ascites2.7811.006-7.6820.049
MELD1.1541.067-1.248< 0.0012.6911.261-5.7400.01
MELD ≥ 183.8271.190-12.3150.0244.3691.255-15.2150.021
Na, mmol/L0.9450.870-1.0270.180
UKELD1.1211.029-1.2200.0091.1171.037-1.2040.003
Table 3 Univariate and multivariate analysis of factors associated with 1-year post-transplant patient and graft survival of retransplanted patients on Cox proportional hazard analysis
VariablePatient survival
Graft survival
HR95%CIP valueHR95%CIP value
Univariate analysis
Age0.7960.973-1.0210.9970.9920.969-1.0160.515
Early graft dysfunction2.1430.919-4.9980.0781.7880.776-4.1230.173
DM2.2420.961-5.2280.0622.0040.869-4.6180.103
Renal impairment4.3852.133-9.017< 0.0013.4941.759-6.941< 0.001
CCI continuous3.3441.949-5.738< 0.0012.7551.638-4.633< 0.001
CCI dichotomous3.561.691-7.4930.0012.7511.377-5.4940.004
Pre-LRT mechanical ventilation3.0441.461-6.3420.0032.4561.210-4.9830.013
Pre-LRT vasopressor support4.7142.239-9.928< 0.0013.6181.758-7.443< 0.001
Pre-LRT renal replacement therapy4.2332.029-8.829< 0.0013.2711.630-6.5620.001
Transplant from ICU2.7441.318-5.7120.0072.1011.049-4.2060.036
MELD score ≥ 184.7142.239-9.9280.0093.1051.399-6.8900.005
Encephalopathy at LRT2.5931.213-5.5440.0142.281.121-4.6390.023
Hb, g/dL0.7910.629-0.9940.0440.7920.636-0.9850.037
ABO mismatch2.371.015-5.5320.0462.3381.053-5.1900.037
Cold ischemia time (h)1.1130.987-1.2550.0821.0810.962-1.2160.191
DRI0.680.236-1.9630.4760.6930.250-1.9180.476
DRI > 1.81.7360.772-3.9020.1801.670.747-3.7370.212
Multivariate analysis
Renal impairment3.2151.147-12.6030.0052.5431.160-5.5730.020
CCI Continuous2.8231.563-5.1010.0012.3501.331-4.1480.003
CCI Dichotomous2.871.306-6.3070.0092.2231.067-4.6330.033
Pre-LRT mechanical ventilation2.521.126-5.6370.0242.0990.968-4.5520.060
Pre-LRT vasopressor support4.0041.554-10.3140.0043.0231.216-7.5140.017
Pre-LRT renal replacement therapy2.6911.261-5.7400.012.4411.107-5.3830.027
Transplant from ICU1.8590.794-4.3540.1531.4370.640-3.2300.380
MELD score ≥ 182.5061.044-6.0180.042.5121.098-5.7430.029
Encephalopathy at LRT1.9220.856-4.3150.1131.6260.752-3.5150.217
Hb, g/dL at LRT0.8830.694-1.1250.3140.8830.698-1.1160.297
ABO mismatch1.7950.739-43630.1971.8270.791-4.2200.158
Table 4 Comparison of prognostic variables according to time interval of liver retransplantation
Time between transplants (d)0-7 (n = 19)8-30 (n = 16)> 30 (n = 86)P value
Age54 (18-67)44 (20-63)43 (19-70)0.086
Transplant MELD22 (10-40)17 (8-36)17 (6-31)0.104
CCI ≥ 1, n (%)10 (71)11 (61)44 (49)0.095
Indication, n (%)
Early graft dysfunction14 (74)2 (13)2 (2)< 0.001
Graft rejection0 (0)1 (6)30 (35)< 0.001
Vascular5 (26)13 (81)23 (27)< 0.001
Disease recurrence0 (0)0 (0)24 (28)0.001
Other indications0 (0)0 (0)7 (8)0.106